title: Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?
abstract: METHODS
  We present a case of a 63-year-old Chinese female who developed severe thrombocytopenia after receiving olsalazine 1.5 g daily for 3 months, and eventually culminated in hospital admission. According to a Medline search, this is the first case report of olsalazine-associated thrombocytopenia in Asia.
  
  
  CONCLUSIONS
  Olsalazine, similar to other 5-aminosalicylates, can also cause thrombocytopenia. Clinicians should be aware of this potential adverse drug reaction. Future studies should focus on the trigger mechanism and possible cross-reaction between olsalazine and other aminosalicylates.
authors.affiliation: The First Affiliated Hospital, College of Medicine, Zhejiang University, HangZhou, China.
authors.forename: Yuefeng
authors.initials: Y
authors.lastname: Rao
authors.forename: Feiyue
authors.initials: F
authors.lastname: Zheng
mesh_terms: D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D008875:Middle Aged; D011355:Prodrugs; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D011355:Prodrugs; C032587:olsalazine